Cytokinetics (CYTK) FY2019 results: revenue $27 million, down 14.7% on the year
Cytokinetics Inc. (CYTK) reported revenue of $27 million for fiscal 2019, the year ended 31 December 2019, down 14.7% on the year before. Net income was -$122 million, and diluted earnings per share $-2.11. The figures are the company's own, from the 10-K it filed with the SEC on 4 March 2020.
Revenue
$27 million
-14.7% on the year
FY2012FY2019
Operating margin
-368.0%
-282.3% a year earlier
FY2012FY2019
Net income
-$122 million
FY2012FY2019
Diluted EPS
-$2.11
FY2012FY2019
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Revenue
26.9
31.5
13.4
-14.7%
Research and development
86.1
89.1
90.3
-3.4%
Operating income
-98.9
-88.9
-113
Operating margin
-368.0%
-282.3%
-848.3%
Interest expense
6.6
3.8
3.0
+74.4%
Pre-tax income
n/a
-106
-128
Income tax
0.0
0.0
0.0
Net income
-122
-106
-128
Net margin
-452.9%
-337.4%
-955.9%
Diluted EPS
-$2.11
-$1.95
-$2.59
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Operating cash flow
-90.9
-101
-102
Capital expenditure
2.6
0.9
2.9
+194.6%
Free cash flow
-93.5
-102
-105
Free cash flow margin
-348.1%
-324.1%
-782.7%
Cash from investing
-74.7
5.1
-65.8
Cash from financing
160
13.1
226
+1,116.8%
Depreciation and amortisation
1.3
1.2
1.9
+4.4%
Share-based compensation
10.8
9.8
9.0
+10.2%
Diluted shares, weighted
n/a
n/a
49m
Shares outstanding at period end
59m
55m
54m
+8.1%
Balance sheet
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Shareholders' equity
-10.9
25.9
110
Debt
129
42.4
31.8
+204.8%
Operating lease liabilities
2.2
0.8
n/a
+184.7%
Other liabilities
169
142
153
+19.2%
Total liabilities and equity
290
211
295
+37.2%
Fixed assets
4.5
3.2
3.6
+41.4%
Investments
231
156
160
+47.8%
Cash and equivalents
36.4
42.3
125
-13.8%
Receivables
5.2
2.2
1.1
+131.4%
Other assets
12.4
7.0
4.7
+76.3%
Total assets
290
211
295
+37.2%
10-K for the year ended 31 December 2019, filed 4 March 2020: the filing.